Safety and Efficacy of Aficamten in Patients With Non-obstructive Hypertrophic Cardiomyopathy: A 36-week Analysis From FOREST-HCM

Discovery of Aficamten (CK-274): Next-in-class Cardiac myosin inhibitor (CMI) for obstructive Hypertrophic Cardiomyopathy (oHCM)

Associations Between Sex and Cardiovascular Outcomesin Patients with Hypertrophic Cardiomyopathy

Comparisons in Cardiovascular Outcomes and Mortality in Patients Diagnosed with Hypertrophic Cardiomyopathy

SEQUOIA-HCM: Enhancing Exercise Response in Obstructive Hypertrophic Cardiomyopathy

SEQUOIA-HCM: Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy

SEQUOIA-HCM: Aficamten for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Longitudinal Analyses of Healthcare Resource Utilization and Costs Among Patients With Obstructive Hypertrophic Cardiomyopathy

Assessing Disparities in Cardiovascular Outcomes Across Payers in Patients Diagnosed with Hypertrophic Cardiomyopathy